Zobrazeno 1 - 10
of 293
pro vyhledávání: '"Byoung S, Kwon"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/038f1a85f0cd4fbda07745d083f748d6
Autor:
Eunjung Cho, Seongeun Han, Hyeon Seok Eom, Sang-Jin Lee, Chungyong Han, Rohit Singh, Seon-Hee Kim, Bo-Mi Park, Byoung-Gie Kim, Young H. Kim, Byoung S. Kwon, Ki Taek Nam, Beom K. Choi
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 13672 (2023)
The interaction between regulatory T (Treg) cells and self-reactive T cells is a crucial mechanism for maintaining immune tolerance. In this study, we investigated the cross-activation of Treg cells by self-antigens and its impact on self-reactive CD
Externí odkaz:
https://doaj.org/article/76ddb09bda3f45e68db6b67552ee2300
Autor:
Yichen Wang, Xuyao Zhang, Caili Xu, Yanyang Nan, Jiajun Fan, Xian Zeng, Byoung S. Kwon, Dianwen Ju
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionAlthough PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecu
Externí odkaz:
https://doaj.org/article/526d979fc550427ca12da3dbd2615014
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Lymphodepleting preconditioning is generally required prior to adoptive T cell therapy (ACT). Here the authors show in a preclinical melanoma model that anti-CD4 treatment as a post-conditioning regimen enhances the anti-tumor efficacy of ACT by prom
Externí odkaz:
https://doaj.org/article/9147d37f906c45f8af5f6a7e0c3e7b98
Autor:
Chungyong Han, Beom K. Choi, Seon-Hee Kim, Su-Jung Sim, Seongeun Han, Bomi Park, Yohei Tsuchiya, Masaki Takahashi, Young H. Kim, Hyeon-Seok Eom, Tetsuya Kitaguchi, Hiroshi Ueda, Byoung S. Kwon
Publikováno v:
Molecular Therapy: Oncolytics, Vol 17, Iss , Pp 293-305 (2020)
Antibody applications in cancer immunotherapy involve diverse strategies, some of which redirect T cell-mediated immunity via engineered antibodies. Affinity is a trait that is crucial for these strategies, as optimal affinity reduces unwanted side e
Externí odkaz:
https://doaj.org/article/acf1bdb53f654d41b558e946df7d246b
Autor:
Chungyong Han, Su-Jung Sim, Seon-Hee Kim, Rohit Singh, Sunhee Hwang, Yu I. Kim, Sang H. Park, Kwang H. Kim, Don G. Lee, Ho S. Oh, Sangeun Lee, Young H. Kim, Beom K. Choi, Byoung S. Kwon
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Engineered T cells with chimeric antigen receptor (CAR) are emerging as an effective cancer therapy. Here the authors show that CAR T cells recognizing self-MHC can be ‘tuned’ ex vivo via CAR downregulation and CAR T cell death to generate a CAR
Externí odkaz:
https://doaj.org/article/2cb448a0b80d4a85bfbe75a3ddee2e23
Autor:
Eun M. Yu, Eunjung Cho, Rohit Singh, Seon-Hee Kim, Chungyong Han, Seongeun Han, Don G. Lee, Young H. Kim, Byoung S. Kwon, Beom K. Choi
Publikováno v:
Cells, Vol 10, Iss 8, p 2018 (2021)
Adoptive cell therapy (ACT) using tumor-reactive T cells is a promising form of immunotherapy to specifically target cancer. However, the survival and functional maintenance of adoptively transferred T cells remains a challenge, ultimately limiting t
Externí odkaz:
https://doaj.org/article/f64211fdb8e54a23963b4600aa11a84b
Autor:
Byungsuk Kwon, Hong R. Cho, Byoung S. Kwon, Su K. Seo, Hyeon-Woo Lee, Hyeon H. Kim, Juyang Kim, So H. Park, Sang C. Lee, Sang W. Kang
Figure S6. Depletion of NK cells does not affect tumor growth, intratumoral macrophage differentiation and generation of Tc1 cells within tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32570b37e32ccf1425a0efc759dc4057
https://doi.org/10.1158/0008-5472.22418675.v1
https://doi.org/10.1158/0008-5472.22418675.v1
Autor:
Byungsuk Kwon, Hong R. Cho, Byoung S. Kwon, Su K. Seo, Hyeon-Woo Lee, Hyeon H. Kim, Juyang Kim, So H. Park, Sang C. Lee, Sang W. Kang
CD137 (4-1BB) is a T-cell costimulatory molecule, and agonstic CD137 antibodies are currently being evaluated in the clinic as cancer immunotherapy. Recently, it was found that CD137−/− mice or mice injected with agonistic anti-CD137 antibodies e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::476127927b5c7cc2406b99ffce35f70d
https://doi.org/10.1158/0008-5472.c.6510197
https://doi.org/10.1158/0008-5472.c.6510197
Chemotherapy can precondition for immunotherapy by creating an environment for homeostatic lymphoproliferation and eliminating some of the suppressive immune networks. We found that combination therapy with anti-4-1BB and cyclophosphamide (CTX) produ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d12346b4a30f682a46b5e9341068d5c
https://doi.org/10.1158/1535-7163.c.6531951.v1
https://doi.org/10.1158/1535-7163.c.6531951.v1